Get notified of page updates
Education > XRAY > Prostate Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review
1 through 10 of 58

Relevance: High

Strength of Science: High

View Related Clinical Trials

Topic : Cancer disparities in American Indian and Alaska Native populations

Most relevant for: Native Americans and Alaska Natives

The American Cancer Society released a special section in their 2022 Cancer Facts & Figures report that discussed cancer disparities in American Indian and Alaska Native populations in the United States. This review highlights the special section’s main points, including disparities in cancer screening, diagnosis and survival rates in native communities, as well as factors contributing to those disparities. (Posted 12/20/22)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Guideline : Guidelines on exercise, diet, and weight during cancer treatment

Most relevant for: People currently undergoing treatment for cancer

Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Prostate cancer screening may benefit people with Lynch syndrome

Most relevant for: People with Lynch syndrome

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Teens and young adults respond well to learning about familial cancer risk

Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Physical activity may decrease fatigue associated with cancer treatment

Most relevant for: Cancer patients who are experiencing fatigue related to cancer or its treatment.

Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines.  (Posted 8/1/22). Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : The hidden financial burden of treating cancer care symptoms

Most relevant for: People who are experiencing side effects due to cancer treatment or cancer.

Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Do artificial sweeteners increase the risk of cancer?

Most relevant for: People who consume artificial sweeteners

A large study of adults in France suggests that artificial sweeteners may increase the risk of certain cancers. (posted 6/21/2022). Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Metastatic prostate cancer cases increased as screening use declined

Most relevant for: People who are concerned about their own or their loved one’s risk of prostate cancer

The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : New drug approved for metastatic prostate cancer

Most relevant for: People who have been diagnosed with metastatic prostate cancer.

The FDA approved a new treatment for metastatic castration-resistant prostate cancer. They also approved a test that can be used to identify patients who would benefit from this new treatment.  (Posted 5/10/22)

Read More

This Portal Sponsored By:

AstraZeneca